These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38170790)

  • 1. Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.
    Ding JH; Xiao Y; Yang F; Song XQ; Xu Y; Ding XH; Ding R; Shao ZM; Di GH; Jiang YZ
    Sci Transl Med; 2024 Jan; 16(728):eadg7740. PubMed ID: 38170790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cancer-testis gene,
    Gu Y; Wang C; Zhu R; Yang J; Yuan W; Zhu Y; Zhou Y; Qin N; Shen H; Ma H; Wang H; Liu X; Hu Z
    Cancer Biol Med; 2021 Feb; 18(1):74-87. PubMed ID: 33628586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency.
    Yuan P; Ma N; Xu B
    Med Res Rev; 2024 Nov; 44(6):2774-2792. PubMed ID: 38922930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel UCHL
    Song Z; Tu X; Zhou Q; Huang J; Chen Y; Liu J; Lee S; Kim W; Nowsheen S; Luo K; Yuan J; Lou Z
    Cell Death Dis; 2019 May; 10(6):398. PubMed ID: 31113933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer.
    Su GH; Jiang L; Xiao Y; Zheng RC; Wang H; Jiang YZ; Peng WJ; Shao ZM; Gu YJ; You C
    Ann Surg Oncol; 2022 Oct; 29(11):7165-7175. PubMed ID: 35711018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
    Stewart MD; Merino Vega D; Arend RC; Baden JF; Barbash O; Beaubier N; Collins G; French T; Ghahramani N; Hinson P; Jelinic P; Marton MJ; McGregor K; Parsons J; Ramamurthy L; Sausen M; Sokol ES; Stenzinger A; Stires H; Timms KM; Turco D; Wang I; Williams JA; Wong-Ho E; Allen J
    Oncologist; 2022 Mar; 27(3):167-174. PubMed ID: 35274707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
    Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
    Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
    Gourley C; Miller RE; Hollis RL; Ledermann JA
    Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
    Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.